MedTrace Logo

Determining the Optimal Dose of AD-209 in Patients With Essential Hypertension

NCT04218552 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 176

Last updated 2021-07-21

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal dose of AD-209 in patients with Essential Hypertension.

Conditions

  • Hypertension,Essential

Interventions

DRUG

AD209

PO, Once daily(QD), 8weeks

DRUG

Amlodipine low

PO, Once daily(QD), 8weeks

DRUG

Amlodipine high

PO, Once daily(QD), 8weeks

DRUG

Telmisartan

PO, Once daily(QD), 8weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • ChangGu Park, M.D., Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-25
Primary Completion
2021-02-25
Completion
2021-02-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04218552 on ClinicalTrials.gov